PEPTIDES4ALL PT-141 (Bremelanotide) – Melanocortin Agonist for Sexual Function & Neuroendocrine Research

PEPTIDES4ALL PT-141, also known as Bremelanotide, is a synthetic peptide analog of α-melanocyte-stimulating hormone (α-MSH) belonging to the melanocortin receptor agonist family. Initially developed as part of tanning research, PT-141’s profound effects on sexual arousal and erectile function were discovered serendipitously during early clinical studies. Since then, it has become a cornerstone molecule in the study of sexual desire, arousal mechanisms, and central neuroendocrine regulation.

Unlike traditional phosphodiesterase type-5 inhibitors (such as sildenafil or tadalafil), which act peripherally on vascular smooth muscle, PT-141 works centrally by activating melanocortin receptors (MC3R and MC4R) within the hypothalamus, a region of the brain responsible for sexual motivation and autonomic control. This neurogenic mechanism of action makes it particularly valuable for research into central libido modulation, neurotransmitter signaling, and non-vascular pathways of sexual response.

In both preclinical and clinical models, PT-141 has demonstrated rapid, dose-dependent induction of sexual arousal and erectile activity, including in subjects with limited or no response to standard PDE-5 therapies (PubMed; Nature). Moreover, Bremelanotide’s approval for hypoactive sexual desire disorder (HSDD) in premenopausal women underscores its broader potential in exploring female sexual desire pathways and central dopaminergic regulation (PMC).

Beyond sexual function, the melanocortin system has been implicated in energy balance, mood regulation, and neuroprotection, positioning PT-141 as a unique experimental compound for studying neural network plasticity, reward circuits, and hypothalamic signaling.

With its high-purity lyophilized formulation, PEPTIDES4ALL PT-141 provides a robust and reproducible research tool for investigating melanocortin receptor pharmacology, central nervous system peptide signaling, and the neuroendocrine mechanisms underlying arousal, motivation, and stress adaptation.

Scientific Evidence & Research Findings

• Rapid Onset of Erection & Sexual Arousal – In human trials, systemic administration of PT-141 produced dose-dependent increases in erectile activity even in patients with prior inadequate response to PDE-5 inhibitors. https://pubmed.ncbi.nlm.nih.gov/12851303/

• Melanocortin Receptor Agonism – PT-141 binds to central melanocortin receptors (especially MC3R and MC4R), triggering neural signaling pathways in the hypothalamus linked to libido and arousal. https://www.nature.com/articles/3901200

• Efficacy in Erectile Dysfunction – In controlled crossover studies, 4 mg and 6 mg doses significantly improved erectile response over placebo, showing promise as an alternative for ED patients. https://www.nature.com/articles/3901200

• Potential Use in Women’s Sexual Dysfunction – Bremelanotide is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women, indicating its ability to modulate sexual desire beyond male erectile function. https://pmc.ncbi.nlm.nih.gov/articles/PMC8788464/

• Dose-Response & Safety Profile – Doses above 1.0 mg induced statistically significant erectile responses in healthy male subjects; the peptide was generally well tolerated in trials. https://www.nature.com/articles/3901200

Key Research Benefits & Applications

• Unlike PDE-5 inhibitors (which act on peripheral blood vessels), PT-141 works through central neural pathways—so it can induce arousal and erection even without direct visual or tactile stimulation.

• Some studies show co-administration of PT-141 and sildenafil (a PDE-5 inhibitor) has an additive effect, producing stronger erectile responses than sildenafil alone. https://www.sciencedirect.com/science/article/abs/pii/S0090429504012725

• Early research indicates PT-141 may elevate blood pressure modestly and cause nausea, but these side effects tend to be transient and dose-dependent. https://www.nature.com/articles/3901200

Presentation & Handling

• Form: Supplied as lyophilized peptide in sterile vial.
• Reconstitution: Use bacteriostatic water or 2% procaine; swirl gently (do not shake vigorously).
• Storage: Store at –20 °C, protected from light and moisture. After reconstitution, use according to research protocols and handle under sterile conditions.

Intended Use

For research purposes only. Must be handled in accordance with institutional protocols and ethical guidelines.